Probably not affecting hepatic CYPs.

Vascular 5HT-receptor agonist used in migraine.

Eliminated by oxidative deamination via monamine oxidase. CYP 3A4 and2D6 are alo involved in its metabolism. In vitro studies show that almotriptan is not expected to affect the metabolism of CYP-metabolized drugs.

Badminton M (2006): Almotriptan has been used without any adverses effects in a 17 yr old female with VP (no previous attacks).

One report of a possible beginning of an acute porphyric attack in a susceptible female with AIP, but the attack was poorly documented and several other factors could explain the symptoms. This report has therefore not been taken into account in the judgement of the porphyrinogenicity of almotriptan. Uneventful use reported in 1 patients with acute porphyria.